Literature DB >> 2644104

Antithrombotic agents in coronary artery disease.

L Resnekov1, J Chediak, J Hirsh, H D Lewis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2644104     DOI: 10.1378/chest.95.2_supplement.52s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  8 in total

1.  Therapeutic priorities of Canadian internists.

Authors:  A Laupacis; D L Sackett; R S Roberts
Journal:  CMAJ       Date:  1990-02-15       Impact factor: 8.262

Review 2.  Guidelines on oral anticoagulation: second edition. British Society for Haematology. British Committee for Standards in Haematology. Haemostasis and Thrombosis Task Force.

Authors: 
Journal:  J Clin Pathol       Date:  1990-03       Impact factor: 3.411

Review 3.  Common causes of cardiac emboli--left ventricular thrombi and atrial fibrillation.

Authors:  J R Stratton
Journal:  West J Med       Date:  1989-08

Review 4.  Antiplatelet therapy--Part I.

Authors:  S H Goodnight; B M Coull; J H McAnulty; L M Taylor
Journal:  West J Med       Date:  1993-04

Review 5.  Risk-benefit assessment of anticoagulant therapy.

Authors:  R Harrington; J Ansell
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

Review 6.  Optimal treatment after acute myocardial infarction in the elderly.

Authors:  J Herlitz; M Hartford; M Dellborg; B W Karlson
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

7.  Outcomes research in the development and evaluation of practice guidelines.

Authors:  Louise Pilote; Ira B Tager
Journal:  BMC Health Serv Res       Date:  2002-03-25       Impact factor: 2.655

8.  Fabrication and Characterization of a Magnetic Drilling Actuator for Navigation in a Three-dimensional Phantom Vascular Network.

Authors:  Sunkey Lee; Seungmin Lee; Sangwon Kim; Chang-Hwan Yoon; Hun-Jun Park; Jin-Young Kim; Hongsoo Choi
Journal:  Sci Rep       Date:  2018-02-27       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.